Cargando…
Association of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with risk of COVID‐19, inflammation level, severity, and death in patients with COVID‐19: A rapid systematic review and meta‐analysis
An association among the use of angiotensin converting enzyme (ACE) inhibitors and angiotensin‐receptor blockers (ARBs) with the clinical outcomes of coronavirus disease 2019 (COVID‐19) is unclear. PubMed, EMBASE, MedRxiv, and BioRxiv were searched for relevant studies that assessed the association...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wiley Periodicals, Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7436520/ https://www.ncbi.nlm.nih.gov/pubmed/32757246 http://dx.doi.org/10.1002/clc.23421 |
_version_ | 1783572531520733184 |
---|---|
author | Liu, Xiao Long, Chuyan Xiong, Qinmei Chen, Chen Ma, Jianyong Su, Yuhao Hong, Kui |
author_facet | Liu, Xiao Long, Chuyan Xiong, Qinmei Chen, Chen Ma, Jianyong Su, Yuhao Hong, Kui |
author_sort | Liu, Xiao |
collection | PubMed |
description | An association among the use of angiotensin converting enzyme (ACE) inhibitors and angiotensin‐receptor blockers (ARBs) with the clinical outcomes of coronavirus disease 2019 (COVID‐19) is unclear. PubMed, EMBASE, MedRxiv, and BioRxiv were searched for relevant studies that assessed the association between application of ACEI/ARB and risk of COVID‐19, inflammation level, severity COVID‐19 infection, and death in patients with COVID‐19. Eleven studies were included with 33 483 patients. ACEI/ARB therapy might be associated with the reduced inflammatory factor (interleukin‐6) and elevated immune cells counts (CD3, CD8). Meta‐analysis showed no significant increase in the risk of COVID‐19 infection (odds ratio [OR]: 0.95, 95%CI: 0.89‐1.05) in patients receiving ACEI/ARB therapy, and ACEI/ARB therapy was associated with a decreased risk of severe COVID‐19 (OR: 0.75, 95%CI: 0.59‐0.96) and mortality (OR: 0.52, 95%CI: 0.35‐0.79). Subgroup analyses showed among the general population, ACEI/ARB therapy was associated with reduced severe COVID‐19 infection (OR: 0.79, 95%CI: 0.60‐1.05) and all‐cause mortality (OR: 0.31, 95%CI: 0.13‐0.75), and COVID‐19 infection (OR: 0.85, 95% CI: 0.66‐1.08) were not increased. Among patients with hypertension, the use of an ACEI/ARB was associated with a lower severity of COVID‐19 (OR: 0.73, 95%CI: 0.51‐1.03) and lower mortality (OR: 0.57, 95%CI: 0.37‐0.87), without evidence of an increased risk of COVID‐19 infection (OR: 1.00). On the basis of the available evidence, ACEI/ARB therapy should be continued in patients who are at risk for, or have COVID‐19, either in general population or hypertension patients. Our results need to be interpreted with caution considering the potential for residual confounders, and more well‐designed studies that control the clinical confounders are necessary to confirm our findings. |
format | Online Article Text |
id | pubmed-7436520 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Wiley Periodicals, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-74365202020-08-19 Association of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with risk of COVID‐19, inflammation level, severity, and death in patients with COVID‐19: A rapid systematic review and meta‐analysis Liu, Xiao Long, Chuyan Xiong, Qinmei Chen, Chen Ma, Jianyong Su, Yuhao Hong, Kui Clin Cardiol Reviews An association among the use of angiotensin converting enzyme (ACE) inhibitors and angiotensin‐receptor blockers (ARBs) with the clinical outcomes of coronavirus disease 2019 (COVID‐19) is unclear. PubMed, EMBASE, MedRxiv, and BioRxiv were searched for relevant studies that assessed the association between application of ACEI/ARB and risk of COVID‐19, inflammation level, severity COVID‐19 infection, and death in patients with COVID‐19. Eleven studies were included with 33 483 patients. ACEI/ARB therapy might be associated with the reduced inflammatory factor (interleukin‐6) and elevated immune cells counts (CD3, CD8). Meta‐analysis showed no significant increase in the risk of COVID‐19 infection (odds ratio [OR]: 0.95, 95%CI: 0.89‐1.05) in patients receiving ACEI/ARB therapy, and ACEI/ARB therapy was associated with a decreased risk of severe COVID‐19 (OR: 0.75, 95%CI: 0.59‐0.96) and mortality (OR: 0.52, 95%CI: 0.35‐0.79). Subgroup analyses showed among the general population, ACEI/ARB therapy was associated with reduced severe COVID‐19 infection (OR: 0.79, 95%CI: 0.60‐1.05) and all‐cause mortality (OR: 0.31, 95%CI: 0.13‐0.75), and COVID‐19 infection (OR: 0.85, 95% CI: 0.66‐1.08) were not increased. Among patients with hypertension, the use of an ACEI/ARB was associated with a lower severity of COVID‐19 (OR: 0.73, 95%CI: 0.51‐1.03) and lower mortality (OR: 0.57, 95%CI: 0.37‐0.87), without evidence of an increased risk of COVID‐19 infection (OR: 1.00). On the basis of the available evidence, ACEI/ARB therapy should be continued in patients who are at risk for, or have COVID‐19, either in general population or hypertension patients. Our results need to be interpreted with caution considering the potential for residual confounders, and more well‐designed studies that control the clinical confounders are necessary to confirm our findings. Wiley Periodicals, Inc. 2020-08-05 /pmc/articles/PMC7436520/ /pubmed/32757246 http://dx.doi.org/10.1002/clc.23421 Text en © 2020 The Authors. Clinical Cardiology published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Reviews Liu, Xiao Long, Chuyan Xiong, Qinmei Chen, Chen Ma, Jianyong Su, Yuhao Hong, Kui Association of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with risk of COVID‐19, inflammation level, severity, and death in patients with COVID‐19: A rapid systematic review and meta‐analysis |
title | Association of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with risk of COVID‐19, inflammation level, severity, and death in patients with COVID‐19: A rapid systematic review and meta‐analysis
|
title_full | Association of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with risk of COVID‐19, inflammation level, severity, and death in patients with COVID‐19: A rapid systematic review and meta‐analysis
|
title_fullStr | Association of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with risk of COVID‐19, inflammation level, severity, and death in patients with COVID‐19: A rapid systematic review and meta‐analysis
|
title_full_unstemmed | Association of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with risk of COVID‐19, inflammation level, severity, and death in patients with COVID‐19: A rapid systematic review and meta‐analysis
|
title_short | Association of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with risk of COVID‐19, inflammation level, severity, and death in patients with COVID‐19: A rapid systematic review and meta‐analysis
|
title_sort | association of angiotensin converting enzyme inhibitors and angiotensin ii receptor blockers with risk of covid‐19, inflammation level, severity, and death in patients with covid‐19: a rapid systematic review and meta‐analysis |
topic | Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7436520/ https://www.ncbi.nlm.nih.gov/pubmed/32757246 http://dx.doi.org/10.1002/clc.23421 |
work_keys_str_mv | AT liuxiao associationofangiotensinconvertingenzymeinhibitorsandangiotensiniireceptorblockerswithriskofcovid19inflammationlevelseverityanddeathinpatientswithcovid19arapidsystematicreviewandmetaanalysis AT longchuyan associationofangiotensinconvertingenzymeinhibitorsandangiotensiniireceptorblockerswithriskofcovid19inflammationlevelseverityanddeathinpatientswithcovid19arapidsystematicreviewandmetaanalysis AT xiongqinmei associationofangiotensinconvertingenzymeinhibitorsandangiotensiniireceptorblockerswithriskofcovid19inflammationlevelseverityanddeathinpatientswithcovid19arapidsystematicreviewandmetaanalysis AT chenchen associationofangiotensinconvertingenzymeinhibitorsandangiotensiniireceptorblockerswithriskofcovid19inflammationlevelseverityanddeathinpatientswithcovid19arapidsystematicreviewandmetaanalysis AT majianyong associationofangiotensinconvertingenzymeinhibitorsandangiotensiniireceptorblockerswithriskofcovid19inflammationlevelseverityanddeathinpatientswithcovid19arapidsystematicreviewandmetaanalysis AT suyuhao associationofangiotensinconvertingenzymeinhibitorsandangiotensiniireceptorblockerswithriskofcovid19inflammationlevelseverityanddeathinpatientswithcovid19arapidsystematicreviewandmetaanalysis AT hongkui associationofangiotensinconvertingenzymeinhibitorsandangiotensiniireceptorblockerswithriskofcovid19inflammationlevelseverityanddeathinpatientswithcovid19arapidsystematicreviewandmetaanalysis |